Innovative Industrial Properties Inc (IIPR) Stock Price Today
Aura AI Summary
Key Stats
- $1.87BMarket Cap
- -Volume
- Real EstateSector
- $64.6752W High
- $44.5852W Low
- -Typical Hold Time
- $2.25BEnterprise Value
- 11.79%Div Yield
- -Trading Activity
Track Innovative Industrial Properties Inc (IIPR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Innovative Industrial Properties Inc has traded between a low of $44.58 and a high of $64.67, highlighting its annual price range. Buy and sell Innovative Industrial Properties Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Most Recent News
US chip stocks fall on fears over new Chinese Kimi K3 model, despite strong earnings from TSMC and ASML.
US semiconductor stocks dropped sharply after the introduction of a new Chinese chip model called Kimi K3, which rattled investors despite strong earnings and raised guidance from major players like TSMC and ASML. The SOXX ETF fell 1.5%, reflecting b...
S&P 500 falls 1.6% as investors shift from growth to value amid inflation and geopolitical concerns
Last week, the S&P 500 dropped 1.6% as investors moved away from large-cap growth stocks toward value and defensive sectors. Energy and commodities outperformed, while technology and momentum stocks lagged due to renewed geopolitical tensions and inf...
Medicus Pharma's redesigned Teverelix study gets FDA and IRB approval, cutting costs and patient numbers significantly.
Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.